← All reports

Huahui Health and BeOne Medicines have entered into a global exclusive agreement to develop and commercialize the innovative oncology drug HH160.

HealthcarePharmaceutical IndustryMay 5, 2026score 0.172 posts · 0 replies across 1 instances
The thread discusses a collaboration agreement between Huahui Health and BeOne Medicines for an innovative oncology drug, HH160, highlighting a significant development in the pharmaceutical industry.

Claims

Huahui Health and BeOne Medicines have entered into a global exclusive agreement to develop and commercialize the innovative oncology drug HH160.
Parent: Pharmaceutical IndustryEntity: Huahui Health and BeOne MedicinesSub-entity: HH160Impact: positiveDate: May 5, 2026Target: The collaboration between Huahui Health and BeOne Medicines for the development and commercialization of HH160.

Source posts

@[email protected]
Huahui Health and BeOne Medicines Enter into a Global Exclusive Option, License and Collaboration Agreement for Innovative Oncology Drug HH160 https://www.thehindu.com/brandhub/pr-release/huahui-health-and-beone-medicines-enter-into-a-global-exclusive-option-license-and-collaboration-agreement-for-innovative-oncology-drug-hh160/article70942165.ece?utm_source=flipboard&utm_medium=activitypub Posted into The Hindu @the-hindu-TheHindu
0 boosts · 0 favs · 0 replies · May 5, 2026
@[email protected]
Huahui Health and BeOne Medicines Enter into a Global Exclusive Option, License and Collaboration Agreement for Innovative Oncology Drug HH160 https://www.thehindu.com/brandhub/pr-release/huahui-health-and-beone-medicines-enter-into-a-global-exclusive-option-license-and-collaboration-agreement-for-innovative-oncology-drug-hh160/article70942277.ece?utm_source=flipboard&utm_medium=activitypub Posted into The Hindu @the-hindu-TheHindu
0 boosts · 0 favs · 0 replies · May 5, 2026